Equities analysts expect that Ovid Therapeutics Inc (NASDAQ:OVID) will post ($0.49) earnings per share for the current quarter, Zacks reports. Zero analysts have made estimates for Ovid Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.46) and the lowest estimate coming in at ($0.51). Ovid Therapeutics reported earnings per share of ($0.53) in the same quarter last year, which suggests a positive year-over-year growth rate of 7.5%. The business is expected to issue its next quarterly earnings report on Thursday, August 8th.
According to Zacks, analysts expect that Ovid Therapeutics will report full year earnings of ($1.84) per share for the current fiscal year, with EPS estimates ranging from ($2.15) to ($1.52). For the next year, analysts anticipate that the company will report earnings of ($2.41) per share, with EPS estimates ranging from ($4.55) to ($0.53). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Ovid Therapeutics.
Ovid Therapeutics (NASDAQ:OVID) last issued its earnings results on Tuesday, May 7th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.04).
Several hedge funds and other institutional investors have recently modified their holdings of the company. Jane Street Group LLC bought a new stake in Ovid Therapeutics during the 1st quarter valued at approximately $31,000. Rhumbline Advisers boosted its stake in Ovid Therapeutics by 47.2% during the 4th quarter. Rhumbline Advisers now owns 16,551 shares of the company’s stock valued at $40,000 after purchasing an additional 5,310 shares during the period. SG Americas Securities LLC bought a new stake in Ovid Therapeutics during the 4th quarter valued at approximately $46,000. Oxford Asset Management LLP boosted its stake in Ovid Therapeutics by 160.2% during the 1st quarter. Oxford Asset Management LLP now owns 61,066 shares of the company’s stock valued at $108,000 after purchasing an additional 37,599 shares during the period. Finally, Two Sigma Investments LP bought a new stake in Ovid Therapeutics during the 4th quarter valued at approximately $114,000. 31.73% of the stock is currently owned by institutional investors and hedge funds.
Shares of OVID stock opened at $1.77 on Monday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.78 and a current ratio of 7.78. Ovid Therapeutics has a fifty-two week low of $1.53 and a fifty-two week high of $11.45.
About Ovid Therapeutics
Ovid Therapeutics Inc, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome.
Recommended Story: How to Invest in the Dividend Aristocrat Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.